Pluri Inc.
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
NV
Country
Israel
Business Address
MATAM ADVANCED TECHNOLOGY PARK, HAIFA, ,
Mailing Address
MATAM ADVANCED TECHNOLOGY PARK, HAIFA, ,
Phone
972-74-710-7171
Fiscal Year End
0630
EIN
980351734
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 12, 2026 | View on SEC |
| 8-K Current report of material events | January 22, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | December 15, 2025 | View on SEC |
| 8-K Current report of material events | December 9, 2025 | View on SEC |
| 4 Insider stock transaction report | December 8, 2025 | View on SEC |
| 4 Insider stock transaction report | December 8, 2025 | View on SEC |
Annual Reports
10-K
September 17, 2025
- Progressed lung injury treatment toward FDA trials
- Partnered with Ukraine’s Hemafund for radiation therapy drug PLX-R18
Material Events
8-K
Financial Distress
March 2, 2026
High Impact
- Pluri Inc. successfully resolved its Nasdaq listing concerns, ensuring its continued presence on the exchange.
- The company has regained compliance with Nasdaq's minimum market value requirement, closing the delisting matter.
8-K
Financial Distress
January 22, 2026
High Impact
- Pluri Inc. received a Nasdaq delisting warning on January 20, 2026, for failing multiple listing standards.
- The company's Market Value of Listed Securities (MVLS) is $20 million, significantly below the Nasdaq's $35 million requirement.
Related Companies
Companies in the same industry (SIC: 2836)
Kodiak Sciences Inc.
KOD
Biological Products, (No Diagnostic Substances)
BioAtla, Inc.
BCAB
Biological Products, (No Diagnostic Substances)
Cardiff Oncology, Inc.
CRDF
Biological Products, (No Diagnostic Substances)
HALOZYME THERAPEUTICS, INC.
HALO
Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corp
ADPT
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.